公开(公告)号：US10329563B2

公开(公告)日：2019-06-25

申请号：US15587538

申请日：2017-05-05

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Jinyun Chen ,  Kalyani Gampa ,  Dieter Huesken ,  Frank Stegmeier ,  Mark Stump ,  Chandra Vargeese ,  Jan Weiler ,  Wenlai Zhou

IPC分类号： C07H21/04 ,  C12N15/113 ,  A61K31/5377 ,  A61K31/713 ,  A61K45/06

摘要： The present disclosure relates to methods of treating heat stock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

公开(公告)号：US20170298354A1

公开(公告)日：2017-10-19

申请号：US15587538

申请日：2017-05-05

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Jinyun Chen ,  Kalyani Gampa ,  Dieter Huesken ,  Frank Stegmeier ,  Mark Stump ,  Chandra Vargeese ,  Jan Weiler ,  Wenlai Zhou

IPC分类号： C12N15/113 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/713

CPC分类号： C12N15/113 ,  A61K31/5377 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/333 ,  C12N2310/334 ,  C12N2310/335 ,  C12N2310/336 ,  C12N2310/351 ,  C12N2320/31 ,  C12N2310/3521 ,  C12N2310/3525

摘要： The present disclosure relates to methods of treating heat stock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

公开(公告)号：US20190323008A1

公开(公告)日：2019-10-24

申请号：US16450967

申请日：2019-06-24

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Jinyun Chen ,  Kalyani Gampa ,  Dieter Huesken ,  Frank Stegmeier ,  Mark Stump ,  Chandra Vargeese ,  Jan Weiler ,  Wenlai Zhou

IPC分类号： C12N15/113 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/713

摘要： The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

公开(公告)号：US20180153919A1

公开(公告)日：2018-06-07

申请号：US15258042

申请日：2016-09-07

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Brian Bettencourt ,  Stuart Milstein ,  Ivanka Toudjarska ,  Earl McDonald ,  Michael Schlabach, JR. ,  Frank P. Stegmeier ,  Markus Warmuth ,  Kalyani Gampa ,  Dieter Huesken ,  Mark Stump ,  Jan Weiler ,  Zainab Jagani

IPC分类号： A61K31/713 ,  A61K45/06 ,  A61K47/54 ,  C12N15/113

CPC分类号： A61K31/713 ,  A61K45/06 ,  A61K47/549 ,  C12N15/113 ,  C12N15/1135 ,  C12N2310/14 ,  C12N2310/344 ,  C12N2310/351 ,  C12N2310/321 ,  C12N2310/3521

摘要： The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.